NOVELMED THERAPEUTICS
NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with large market potential and unmet medical need. We specialize in complement-based therapies. Over the last decade, we have generated pre-clinical dat... a and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies target non-orphan and orphan diseases and have the potential for a better safety and efficacy profile than currently marketed drugs
NOVELMED THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2003-01-01
Address:
Cleveland, Ohio, United States
Country:
United States
Website Url:
http://www.novelmed.com
Total Employee:
1+
Status:
Active
Contact:
4408666999
Total Funding:
1.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Euro Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Azaya Therapeutics
Azaya Therapeutics is a biotechnology company developing therapies for cancer and other serious medical conditions.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.novelmed.com
- Host name: a20b9ee60132ef283.awsglobalaccelerator.com
- IP address: 13.248.155.104
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "NovelMed Therapeutics" on Search Engine
Home - Novelmed
NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases. Useful links About Us R&D Strategy Product Pipeline PartnersSee details»
NovelMed Therapeutics - Crunchbase Company Profile & Funding
NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with.See details»
About Us - Novelmed
About Us. NovelMed is a cutting edge clinical-stage biotech. We are a privately-held Ohio based biotechnology company developing novel biologics for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process.See details»
R&D Strategy - Novelmed
NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases. Useful links About Us R&D Strategy Product Pipeline PartnersSee details»
Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for …
Feb 12, 2024 NovelMed Therapeutics Inc. FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH. Ruxoprubart is an Anti-Bb antibody that selectively blocks the alternative...See details»
NovelMed Announces Interim Positive Results from Its Phase I …
CLEVELAND, Feb. 21, 2022 /PRNewswire/ -- NovelMed Therapeutics, Inc. announced today interim positive results from a First-in-Human Phase I clinical trial of its complement blocker monoclonal...See details»
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a
CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program,...See details»
NovelMed Phase I Clinical Trial Shows Inhibition of the
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal...See details»
NovelMed Commences Phase II Trial for Anti-Bb Antibody
CLEVELAND, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal...See details»
Anti-Properdin Antibody (NM3086) Reduced Hemolysis, LDH, …
CLEVELAND, Dec. 12, 2022 /PRNewswire/ -- NovelMed Therapeutics is a clinical-stage biotechnology company focused on developing anti-complement therapies for rare (orphan) diseases. NovelMed...See details»
NovelMed's Complement Alternative Pathway Specific Anti-Bb …
Jan 31, 2022 Novelmed Therapeutics. Jan 31, 2022, 08:00 ET. Share this article. CLEVELAND, Jan. 31, 2022 /PRNewswire/ -- NovelMed Therapeutics announced today that its Investigational New Drug...See details»
NovelMed Commences Phase II Trial for Anti-Bb Antibody …
October 30, 2023 · 4 min read. NovelMed Therapeutics Inc. The Phase I healthy trial revealed that NM8074 effectively blocked the alternative pathway (AP) and AP-mediated C3b deposition without...See details»
Product Pipeline - Novelmed
NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases. Useful links About Us R&D Strategy Product Pipeline PartnersSee details»
NOVELMED THERAPEUTICS, INC. | VentureRadar
"NovelMed Therapeutics is an early stage privately held biotechnology company that has developed cutting-edge therapeutics for rare but complement-mediated diseases. We are a proven leader in the field of rare diseases that are complement-mediated.See details»
NovelMed Therapeutics - Funding, Financials, Valuation & Investors
NovelMed Therapeutics is a biotechnology company developing novel therapies for orphan and non-orphan diseases.See details»
NM 3086 - AdisInsight - Springer
Jun 14, 2023 At a glance. Originator NovelMed Therapeutics. Class Monoclonal antibodies. Mechanism of Action Alternative complement pathway modulators; Complement C3-C5 convertases inhibitors. Orphan Drug Status. Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. No. New …See details»
NM-3086 - Drug Targets, Indications, Patents - Synapse
Apr 5, 2024 NovelMed Therapeutics, Inc. Active Organization. NovelMed Therapeutics, Inc. Inactive Organization - Drug Highest Phase Phase 1. First Approval Date - Regulation Orphan Drug (US) Related. 100 Clinical Results associated with NM-3086. Login to view more data. 100 Patents (Medical) associated with NM-3086. Login to view …See details»
News - Novelmed
NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases. Useful links About Us R&D Strategy Product Pipeline PartnersSee details»
Ruxoprubart - Drug Targets, Indications, Patents - Synapse
Apr 5, 2024 CLEVELAND, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.See details»
Ruxoprubart - NovelMed Therapeutics - AdisInsight - Springer
12 Feb 2024 NovelMed Therapeutics files an IND application with the US FDA in USA for Atypical-haemolytic-uraemic-syndrome, Membranoproliferative-glomerulonephritis, and Anti-neutrophil cytoplasmic antibody-associated vasculitis prior to February 2024.See details»